Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Humana has increased its earnings per share (EPS) estimate for 2025 to $17.06, reflecting strong second-quarter results and revised guidance that indicate solid operational performance. The company's anticipated year-over-year earnings growth for 2027, driven by effective margin initiatives, reinforces optimism regarding its financial trajectory, despite challenges related to star ratings and bonus payments. Additionally, with an above-industry star rating profile in Medicare Advantage and successful environmental sustainability targets, Humana is uniquely positioned to adapt to regulatory changes while enhancing its competitive advantage.

Bears say

The outlook for Humana's stock is negatively impacted by expected declines in earnings per share (EPS) for 2026, primarily due to persistent challenges related to the company's Medicare Advantage (MA) program and competition in the market. Key downside risks include increased utilization of medical assistance, inadequate reimbursement rates, and declining Star ratings, which the company acknowledges could adversely affect the performance of its earnings. Furthermore, the anticipated need for increased investments to enhance Star program outcomes signals a potential strain on financial results, with projections indicating that FY27 EPS may fall approximately 10% short of earlier estimates.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.